Supplier News: Recipharm, CordenPharma, Alcami & More
The latest from CDMOs, CMOs, and suppliers featuring Recipharm, CordenPharma, Coriolis Pharma, Stevanato Group, Alcami, and DHL.
Biologics Manufacturing
Recipharm Acquires Biologics CDMO GenIbet
Recipharm, a CDMO of drug substances and drug products, has acquired GenIbet, an Oeiras, Portugal-based biologics CDMO of recombinant proteins, cell and gene therapies, RNA, live microbial products and vaccines.
The acquisition positions Recipharm in contract service for biologics. GenIbet was founded in 2006 as a spin-off of iBet Instituto de Biologia Experimental e Tecnológica, a private organization specializing in biotechnology research and bioprocess development. It currently has approximately 70 employees. Its Portuguese facility is located in Oeiras, near Recipharm’s facility in Lisbon, Portugal.
Source: Recipharm
Formulation Development/Drug-Product Manufacturing
Recipharm Begins Construction of Fill-Finish Facility
Recipharm, a CDMO of drug substances and drug products, has begun construction on a new fill–finish facility in Morocco.
Last year (July 2021), Recipharm signed a memorandum of understanding with the Moroccan government and a consortium of banks in the country to operate the new facility.
The facility, named Sensyo Pharmatech, will first focus on the manufacture and syringing of vaccines and will feature three industrial lines, which are forecast to produce more than 100 million units in 2024. These lines will be dedicated to producing vials and vaccines in syringes. It is being constructed on a 60-hectare greenfield site and is expected to be operational by 2023.
Between 2022 and 2025, the company says the aim is to transfer the aseptic filling and active substance manufacturing of more than 20 vaccines and biotherapeutic products, including three COVID-19 vaccines, to meet demand in Morocco and Africa.
Source: Recipharm
CordenPharma Acquires Drug-Product Mfg Facilities
CordenPharma has completed the acquisition of three drug-product manufacturing facilities from Vifor Pharma, a specialty pharmaceutical company, to be y renamed Corden Pharma Fribourg S.A. (including its Ettingen branch) in Switzerland, and Corden Pharma Lisbon S.A. in Portugal.
The acquisition of the Vifor Pharma manufacturing sites, first announced last year (December 2021), will expand CordenPharma’s capabilities and capacities in the manufacturing of non-sterile drug-product dosage forms, including but not limited to, oral solid-dosage forms such as tablets and capsules. With the addition of these three new facilities, CordenPharma’s global network now consists of 12 locations (11 GMP sites and 1 R&D laboratory).
Source: CordenPharma
Coriolis Pharma Opens New ATMP Development Facilities
Coriolis Pharma, a Martinsried-Munich, Germany-based contract provider of formulation research and development and analytical testing, has opened new advanced therapy medicinal product (ATMP) development facilities.
After one year of re-construction, the new facilities will increase Coriolis’ capabilities for ATMP development. Formulation development for ATMPs, including cell-culture activities, particle characterization, particle identification and forensic, analytical ultracentrifugation, and a lyophilization development center will be available under Biosafety Level 2 conditions.
The expansion was first announced last year (July 2021).
Source: Coriolis Pharma
Packaging
Stevanato Group Appoints New President, Americas
Stevanato Group, a provider of drug-containment, drug-delivery, and diagnostic products and services, has appointed Riccardo Butta, formerly Senior Vice President, Flex Ltd. a contract service provider, as President, Americas.
Mr. Butta has more than 30 years of management experience, including 20 years with Flex Ltd., In his most recent role as Senior Vice President, Mr. Butta was responsible for the global commercial organization of Flex Health Solutions, a business unit of Flex providing contract design, manufacturing, and logistics services to the healthcare industry with a focus on medical devices, drug-delivery solutions, and medical/life-sciences equipment.
In separate news, the company has extended its pen-injector technology licensing agreement with Haselmeier, a developer and manufacturer of self-injection devices, for its Axis-D pen-injector technology.
The extension provides Stevanato exclusivity to offer the technology to support a broader range of drugs beyond diabetes, including therapeutic areas such as obesity, cardiovascular disease, gastrointestinal disorders, pain management, neurological disorders, arthritis, and other areas.
Using the Axis-D pen injector technology, Stevanato Group has developed its Alina variable-dose and fixed-dose pen injector platform.
Source: Stevanato Group (pen-injector technology) and Stevanato Group (Appointment)
General
Alcami To Expand Analytical Services
Alcami, a CDMO of drug products and provider of analytical testing services, is investing $10 million to expand its analytics services at its facilities in Durham, North Carolina.
The investment doubles the company’s laboratory footprint by adding more than 6700 ft² to its existing laboratory footprint. It also will provide for new equipment and capabilities to enhance drug-substance and drug-product characterization capabilities for biologics and cell and gene therapies.
The expanded footprint will incorporate three different laboratories: one focusing on chromatography and electrophoresis; one housing a wide range of mass spectrometry equipment for characterization and sequencing; and a bioassay lab with a separate cell-culture room.
Source: Alcami
DHL Investing $400 M To Expand US Pharma Distribution
DHL Supply Chain, a global and North American contract logistics company within Deutsche Post DHL Group, has announced that its life-sciences and healthcare sector is investing $400 million to expand its pharmaceutical and medical device distribution network.
DHL’s new investment includes six new US sites by the end of 2022. The expansion will increase the company’s network by nearly 3 million additional square feet and will bring the total number of DHL’s life-sciences and healthcare sites to 34 by the end of 2022. These sites are located across the US in the following: Atlanta, Georgia; Cincinnati, Ohio; Memphis, Tennessee, Reno, Nevada; and Lebanon, Pennsylvania. The new builds will be fully licensed with temperature-controlled and provide integrated operations for both packaging and managed transportation.
Source: DHL Supply Chain
